Live feed07:15:00·11dPRReleaseAbbVie Showcases Late‑Breaking Phase 2 Data for Mirvetuximab Soravtansine-gynx (ELAHERE®) in Platinum‑Sensitive Ovarian Cancer (PSOC) at SGO 2026ABBV· AbbVie Inc.Health CareOriginal source
